Zhongguo fei ai za zhi = Chinese journal of lung cancer
-
Zhongguo Fei Ai Za Zhi · Dec 2009
[A Clinical Observation of Concomitant Therapy of Erlotinib and Whole Brain Radiotherapy in Patients of NSCLC Combined with Brain Metastases.].
Treatments to brain metastases in patients of NSCLC include operation, chemotherapy and radiotherapy, while the disease control rate of brain lesions is not so good, the media survival time is 4-6 months. Tyrosine kinase inhibitor erlotinib can get into blood-brain barrier as reported, and it is used as a effetive method to control brain metastases. The aim of this clinical observation was to evaluate the efficacy and adverse reactions after concomitant therapy of erlotinib and whole brain radiotherapy (WBRT) in patients of NSCLC with brain metastasis. ⋯ The effect of the concomitant of erlotinib and WBRT in patients of NSCLC with brain metastases is better than WBRT alone, and the concomitant therapy is well tolerated.